康龙化成(300759) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥3,098,813,569.89, representing a 16.03% increase compared to ¥2,670,740,738.16 in the same period last year[4] - Net profit attributable to shareholders was ¥305,575,186.04, up 32.54% from ¥230,557,834.70 year-on-year[4] - The adjusted net profit under non-IFRS was ¥349,441,031.17, a 3.14% increase from ¥338,816,299.13 in the previous year[4] - The company's cash flow from operating activities was ¥852,829,144.27, reflecting a 14.38% increase compared to ¥745,630,586.78 in the same period last year[4] - Total operating revenue for the current period reached ¥3,098,813,569.89, an increase of 15.9% compared to ¥2,670,740,738.16 in the previous period[24] - Net profit for the current period was ¥279,654,565.09, compared to ¥215,919,833.12 in the previous period, representing an increase of 29.5%[25] - Basic earnings per share increased by 33.54% year-on-year to RMB 0.1736, reflecting the growth in net profit[12] - Basic earnings per share increased to 0.1736 from 0.1300, marking a growth of 33.1%[26] Revenue Breakdown - Revenue from laboratory services was ¥1,857,202,616.77, with a gross margin of 45.54%, up from 44.14% year-on-year[5] - Revenue from CMC (small molecule CDMO) services increased by 30.44% to ¥693,023,486.59, with a gross margin of 30.44%[5] - Revenue from clinical research services was ¥447,320,929.08, showing an 11.76% increase year-on-year[5] - Revenue from North American clients was ¥200,338.79 million, a 16.81% increase, accounting for 64.65% of total revenue[7] - The company signed new orders with a year-on-year growth of over 10%, particularly in laboratory services and CMC services[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥24,332,822,720.98, a 1.69% increase from ¥23,927,398,321.23 at the end of the previous year[4] - Total current assets decreased to CNY 7,384,443,685.17 from CNY 7,608,179,522.72, representing a decrease of approximately 2.95%[21] - Long-term equity investments increased to CNY 727,361,422.75 from CNY 648,983,149.15, an increase of about 12.06%[21] - Total liabilities increased to CNY 7,206,443,000.00, reflecting a growth of approximately 3.5% compared to the previous period[21] - The total liabilities decreased slightly to ¥9,686,700,206.35 from ¥9,704,526,037.38, a reduction of 0.2%[23] Expenses and Taxation - Research and development expenses increased by 30.56% year-on-year to RMB 122,210,590.15, indicating a continued commitment to R&D investment[12] - Total income tax expenses rose by 59.27% year-on-year to RMB 83,932,205.84, corresponding to the increase in total profit[13] - The company paid $1,398,959,106.45 to employees, an increase from $1,313,660,048.35[29] - The company reported a total tax payment of $146,967,843.36, a decrease from $155,141,776.68[29] Comprehensive Income - Other comprehensive income surged by 1,370.30% year-on-year to RMB 98,545,941.98, mainly due to increases in foreign currency translation differences and cash flow hedging[12] - Other comprehensive income after tax for the current period was ¥110,016,172.44, compared to a loss of ¥53,277,635.07 in the previous period[26] - The company reported a total comprehensive income of ¥389,670,737.53, up from ¥162,642,198.05, indicating a significant increase of 139.5%[26] Cash Flow - Cash inflow from operating activities totaled ¥3,472,049,631.92, compared to ¥3,137,994,335.42 in the previous period, indicating a rise of 10.7%[28] - The net cash flow from operating activities was $852,829,144.27, an increase of 14.4% compared to $745,630,586.78 in the previous period[29] - The total cash outflow from investing activities was $2,181,721,151.04, up from $1,578,554,143.99, resulting in a net cash flow from investing activities of -$1,212,095,238.52[29] - Cash inflow from financing activities was $148,201,518.67, compared to $104,094,412.63 in the previous period, while cash outflow was $247,128,234.59, down from $1,616,695,006.87[29] - The ending balance of cash and cash equivalents was $1,173,579,263.69, down from $4,561,507,266.77[29] Future Plans and Investments - The company plans to invest in new product development and market expansion strategies in the upcoming fiscal year[18] - The company is collaborating with professional institutions for equity investments, indicating a strategic move towards enhancing its investment portfolio[18] - The company has announced a profit distribution plan for the fiscal year 2024, which is expected to be disclosed in detail soon[18] Miscellaneous - The company did not execute any new accounting standards adjustments for the first quarter report[30] - The first quarter report was not audited[30]